Alpha 2.0
Login Register
» Articles » PMID: 38863007

DOPA-decarboxylase is Elevated in CSF, but Not Plasma, in Prodromal and De Novo Parkinson's Disease

Overview
Journal Transl Neurodegener
Publisher Biomed Central
Date 2024 Jun 11
PMID 38863007
Authors
Ellen Appleton
Shervin Khosousi
Michael Ta
Michael Nalls
Andrew B Singleton
Andrea Sturchio
Ioanna Markaki
Wojciech Paslawski
Hirotaka Iwaki
Per Svenningsson
Affiliations
Soon will be listed here.
Citing Articles

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.

Bolsewig K, Willemse E, Sanchez-Juan P, Rabano A, Martinez M, Doecke J Nat Commun. 2025; 16(1):1139.

PMID: 39881147 PMC: 11779843. DOI: 10.1038/s41467-025-56293-z.

References
1.
van Rumund A, Pavelka L, Esselink R, Geurtz B, Wevers R, Mollenhauer B . Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. NPJ Parkinsons Dis. 2021; 7(1):29. PMC: 7979935. DOI: 10.1038/s41531-021-00172-z. View
2.
Siderowf A, Concha-Marambio L, Lafontant D, Farris C, Ma Y, Urenia P . Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023; 22(5):407-417. PMC: 10627170. DOI: 10.1016/S1474-4422(23)00109-6. View
3.
Bloem B, Okun M, Klein C . Parkinson's disease. Lancet. 2021; 397(10291):2284-2303. DOI: 10.1016/S0140-6736(21)00218-X. View
4.
Hadjiconstantinou M, Neff N . Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease. CNS Neurosci Ther. 2008; 14(4):340-51. PMC: 6494005. DOI: 10.1111/j.1755-5949.2008.00058.x. View
5.
Pereira J, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D . DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging. 2023; 3(10):1201-1209. PMC: 10570139. DOI: 10.1038/s43587-023-00478-y. View